We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bioavailability of MK-1439 Experimental Nano Formulations in Healthy Adults (MK-1439-046)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02549040
Recruitment Status : Completed
First Posted : September 14, 2015
Last Update Posted : February 5, 2016
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
This study aims to evaluate and compare the relative bioavailability of different MK-1439 experimental nano formulations (NFs) with that of a MK-1439 film coated tablet.

Condition or disease Intervention/treatment Phase
Human Immunodeficiency Virus-1 (HIV-1) Drug: MK-1439 film coated tablet Drug: MK-1439 NF Phase 1

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Rapid Pharmacokinetic Trial of the Bioavailability of Four MK-1439 Nano Formulations in Healthy Adults
Study Start Date : September 2015
Primary Completion Date : December 2015
Study Completion Date : December 2015
Arms and Interventions

Arm Intervention/treatment
Experimental: MK-1439 fixed sequence treatment
After a minimum 10 hour overnight fast, participants are treated with a single oral dose of MK-1439 over a 5 Period fixed sequence. Each period is separated by a 14 day washout.
Drug: MK-1439 film coated tablet
A single MK-1439 film coated tablet, administered orally at the start of Period 2
Drug: MK-1439 NF
A single MK-1439 NF, administered orally at the start of Periods 1, 3, 4, and 5.


Outcome Measures

Primary Outcome Measures :
  1. Area under the plasma concentration-time curve from time 0 to infinity (AUC 0-inf) of MK-1439 following a single administration of MK-1439 [ Time Frame: Periods 1 to 5 at the following Day 1 time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose ]
  2. Area under the plasma concentration-time curve from time 0 to last time (AUC 0-last) with quantifiable MK-1439 following a single administration of MK-1439 [ Time Frame: Periods 1 to 5 at the following Day 1 time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose ]
  3. Maximum plasma concentration (Cmax) of MK-1439 following a single administration of MK-1439 [ Time Frame: Periods 1 to 5 at the following Day 1 time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose ]
  4. Plasma concentration of MK-1439 at 24 hours post-dose (C24hr) following a single administration of MK-1439 [ Time Frame: Periods 1 to 5: 24 hours post-dose ]
  5. Number of participants who experienced at least one adverse event [ Time Frame: Up to 16 days after last dose of study treatment (up to approximately 92 days) ]
  6. Number of participants who discontinued study due to an adverse event [ Time Frame: Up to 4 days after last dose of study treatment (up to approximately 76 days) ]

Secondary Outcome Measures :
  1. Area under the plasma concentration-time curve from time 0 to 48 hours (AUC 0-48 hr.) post-dose of MK-1439 following a single administration of MK-1439 [ Time Frame: Periods 1 to 5 at the following Day 1 time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours post-dose ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02549040


Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Study Director: Medical Director Merck Sharp & Dohme Corp.
More Information

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT02549040     History of Changes
Other Study ID Numbers: 1439-046
2015-002702-36 ( EudraCT Number )
First Posted: September 14, 2015    Key Record Dates
Last Update Posted: February 5, 2016
Last Verified: February 2016

Additional relevant MeSH terms:
Immunologic Deficiency Syndromes
Acquired Immunodeficiency Syndrome
HIV Infections
Immune System Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases